Focusing in on the Regulatory Landscape for Allogeneic Cell Therapies
Time: 3:30 pm
day: Day Two
Details:
- Examining acceptance criteria expectations around gene editing, toxicity, and potency assays
- Highlighting importance of early CMC work to enable efficient manufacturing scale-up for allogeneic products
- Evaluating opportunities to align global regulatory perspectives on allogeneic therapies
